Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept and ECP for GVHD Prophylaxis in Reduced Intensity HSCT
NCT00639717Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2009
- Primary completion
- Jan 2012
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of etanercept, methoxsalen in graft-versus-host disease (GVHD), sponsored by University of Michigan Rogel Cancer Center. Started Mar 2009; status: completed.
02
Drugs
etanerceptmethoxsalen
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00639717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00639717.